Tango Therapeutics (TNGX) closed at $21.50 on November 6, 2026, up 3.0% from the previous close, on volume of 2,102,016 shares (30-day average 3,962,609).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Seagull With Call Spread | 20-Nov-2620 P : 27 C : 32 C | 2,244 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Tango Therapeutics GAAP EPS of -$0.39
Seeking Alpha News (Mon, 9-Nov 7:17 AM ET)
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Globe Newswire (Wed, 4-Nov 8:30 AM ET)
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Market Chameleon (Fri, 23-Oct 3:06 AM ET)
Globe Newswire (Fri, 23-Oct 6:30 AM ET)
Globe Newswire (Fri, 16-Oct 7:00 AM ET)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Globe Newswire (Tue, 11-Aug 11:00 AM ET)
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Tango Therapeutics trades on the NASDAQ stock market under the symbol TNGX.
As of November 9, 2026, TNGX stock price climbed to $22.80 with 366,308 million shares trading.
TNGX has a beta of 0.79, meaning it tends to be less sensitive to market movements. TNGX has a correlation of 0.01 to the broad based SPY ETF.
TNGX has a market cap of $3.84 billion. This is considered a Mid Cap stock.
Last quarter Tango Therapeutics reported $0 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.05.
In the last 3 years, TNGX traded as high as $34.39 and as low as $1.03.
The top ETF exchange traded funds that TNGX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
TNGX has outperformed the market in the last year with a return of +184.6%, while the SPY ETF gained +13.2%. However, in the most recent history, TNGX shares have underperformed the stock market with its stock returning -21.4% in the last 3 month period and -2.3% for the last 2 week period, while SPY has returned -2.0% and -1.2%, respectively.
TNGX support price is $20.29 and resistance is $22.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNGX shares will trade within this expected range on the day.
